Form 4: Leap Therapeutics COO Augustine Lawlor Reports Stock Option Grant

Augustine Lawlor, COO of Leap Therapeutics, reports the acquisition of stock options.

Summary

• Augustine Lawlor, the Chief Operating Officer of Leap Therapeutics, Inc. (LPTX), filed a Form 4 with the SEC.
• The filing reports the grant of an employee stock option to Lawlor on October 2, 2024, for 85,000 shares of common stock at an exercise price of $2.45 per share.
• The options vest in 36 equal monthly installments starting one month after the grant date, contingent upon continued employment with Leap Therapeutics.
• The options expire on October 2, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally viewed neutrally to positively as it incentivizes management. There are no indications of negative news or concerns.

Positives

• The grant of stock options to the COO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The size of the grant and vesting schedule are typical for a COO-level executive at a company of Leap Therapeutics' size and stage of development.
• Comparable companies such as MacroGenics, Inc. and Immunomedics (prior to acquisition by Gilead) have used similar equity-based compensation strategies.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the COO.
• Employees may see the grant as a sign of the company's commitment to its leadership.

Key Dates